Discounted Cash Flow (DCF) Analysis Levered
AIM ImmunoTech Inc. (AIM)
$0.448
-0.02 (-3.39%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.44 | 0.37 | 0.14 | 0.16 | 0.13 | 0.11 | 0.09 | 0.07 | 0.06 | 0.05 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -7.94 | -10.64 | -9.07 | -10.37 | -13.97 | -6.05 | -4.86 | -3.91 | -3.14 | -2.52 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.07 | -0.13 | -0.37 | -0.59 | -0.63 | -0.25 | -0.20 | -0.16 | -0.13 | -0.10 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -8.01 | -10.77 | -9.43 | -10.96 | -14.60 | -6.30 | -5.06 | -4.07 | -3.27 | -2.63 |
Weighted Average Cost Of Capital
| Share price | $ 0.448 |
|---|---|
| Beta | -0.295 |
| Diluted Shares Outstanding | 47.34 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 44.97% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 2.218 |
| Total Debt | 0.15 |
| Total Equity | 21.21 |
| Total Capital | 21.36 |
| Debt Weighting | 0.70 |
| Equity Weighting | 99.30 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.44 | 0.37 | 0.14 | 0.16 | 0.13 | 0.11 | 0.09 | 0.07 | 0.06 | 0.05 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.94 | -10.64 | -9.07 | -10.37 | -13.97 | -6.05 | -4.86 | -3.91 | -3.14 | -2.52 |
| Capital Expenditure | -0.07 | -0.13 | -0.37 | -0.59 | -0.63 | -0.25 | -0.20 | -0.16 | -0.13 | -0.10 |
| Free Cash Flow | -8.01 | -10.77 | -9.43 | -10.96 | -14.60 | -6.30 | -5.06 | -4.07 | -3.27 | -2.63 |
| WACC | ||||||||||
| PV LFCF | -6.15 | -4.82 | -3.77 | -2.96 | -2.32 | |||||
| SUM PV LFCF | -20.01 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 2.52 |
| Free cash flow (t + 1) | -2.68 |
| Terminal Value | -514.98 |
| Present Value of Terminal Value | -454.73 |
Intrinsic Value
| Enterprise Value | -474.74 |
|---|---|
| Net Debt | -31.94 |
| Equity Value | -442.79 |
| Shares Outstanding | 47.34 |
| Equity Value Per Share | -9.35 |